Search clinical trials for: AAB-003 (PF-05236812)

Total 216 results

Aadi Bioscience, Inc.

Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Cancer | Endometrial Cancer | Tumor | Recurrent Endometrial Carcinoma | Endometrioid Endometrial Cancer | Endometrioid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and...

United States
City of Hope Medical Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

Ovarian Cancer | Peritoneal Cavity Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Nelum Corp
Apices Soluciones S.L.; Agenus Inc.

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer (NUMANTIA)

Pancreatic Ductal Adenocarcinoma

Spain
Celgene Corporation

Withdrawn

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Metastatic Melanoma
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma

United States
Aadi Bioscience, Inc.

Recruiting

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Tumor | NET | Pulmonary Neuroendocrine Tumor

United States
Celgene

Terminated

First Line Therapy for Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Canada
Aadi Bioscience, Inc.

Recruiting

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

Advanced Solid Tumor | Tumor | Tumor, Solid

United States
M.D. Anderson Cancer Center
Celgene

Completed

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Colorectal Cancer | Cancer of Gastrointestinal Tract

United States
Peptomyc S.L.

Recruiting

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC (OMO-103-02)

Metastatic Pancreatic Cancer

Spain
Aadi Bioscience, Inc.

Active, not recruiting

ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Inflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative

United States
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
Mirati Therapeutics Inc.
Aadi Bioscience, Inc.

Active, not recruiting

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NSCLC | Metastatic Cancer | Advanced Cancer | Solid Tumor, Adult | Malignant Neoplastic Disease

United States
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
University of Texas Southwestern Medical Center
BerGenBio ASA; Translational Genomics Research Institute; Triligent International

Terminated

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Cancer of Pancreas

United States
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Dental Anesthesia in Pregnant Women With Rheumatic Heart Disease

Pregnancy | Dental Caries | Rheumatic Heart Disease

Brazil
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Pfizer

Terminated

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Pfizer
Academic GI Cancer Consortium (AGICC)

Terminated

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Metastatic Cancer Pancreas

United States
Celgene

Completed

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States, Canada
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Chinese PLA General Hospital

Unknown

Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

Cancer of Pancreas

China
University of Maryland, Baltimore

Withdrawn

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Breast Cancer | Non-Small Cell Lung Cancer | Prostate Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
M.D. Anderson Cancer Center
280Bio Inc

Recruiting

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Advanced Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7 | Postmenopausal | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Pancreas Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Recurrent Ovarian Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Endometrial Carcinoma | Stage III Bladder Cancer | Cervical Squamous Cell Carcinoma | Stage IV Breast Cancer | Malignant Uterine Neoplasm | Recurrent Bladder Carcinoma | Recurrent... and other conditions

United States
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Sarcoma Oncology Research Center, LLC
Aadi Bioscience, Inc.

Completed

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Ewing Sarcoma | Non Small Cell Lung Cancer | Chordoma | Urothelial Carcinoma | Classical Hodgkin Lymphoma | PEComa | Desmoid Tumor | Epithelioid Sarcoma | Squamous Cell Carcinoma | MTOR Activating Mutation

United States
Henry M. Jackson Foundation for the Advancement...
US Military HIV Research Program; Janssen Vaccines & Prevention B.V.

Withdrawn

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission (RV582)

HIV-1-infection

Thailand
M.D. Anderson Cancer Center
Celgene

Completed

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Melanoma

United States
Celgene

Completed

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (abound2L+)

Carcinoma, Non-Small-Cell Lung

United States, Canada, France, Germany, Italy, Spain, United Kingdom
Trishula Therapeutics, Inc.

Completed

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Lymphoma | Solid Tumor

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
Celgene

Terminated

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Pancreatic Neoplasms | Cholestasis

United States, Germany
Samsung Medical Center

Completed

Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Korea, Republic of
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Hospital de La Luz
Claudia Palacio Pastrana, M.D., M.Sc.; Samuel J. Avalos Lara, M.D.; Hector Perez... and other collaborators

Completed

Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery

Cataract | Demodex Infestation | Demodicosis

Mexico
Emory University
National Cancer Institute (NCI); Lexicon Pharmaceuticals

Active, not recruiting

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Recurrent Pancreatic Adenocarcinoma

United States
Celgene

Completed

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer (PANC-001)

Pancreatic Neoplasms

China
SCRI Development Innovations, LLC
Genentech, Inc.; Celgene Corporation

Completed

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Breast Cancer

United States

Search clinical trials for: AAB-003 (PF-05236812)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations